apnea has been researched along with Deafness in 4 studies
Apnea: A transient absence of spontaneous respiration.
Deafness: A general term for the complete loss of the ability to hear from both ears.
| Excerpt | Relevance | Reference |
|---|---|---|
| "3%) had been enrolled in the randomized, placebo-controlled Caffeine for Apnea of Prematurity trial between 1999 and 2004." | 9.16 | Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. ( Anderson, PJ; Asztalos, EV; Barrington, KJ; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2012) |
| "Methylxanthine therapy reduces the frequency of apnea and the need for mechanical ventilation." | 8.82 | Methylxanthine therapy for apnea of prematurity: evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial. ( Schmidt, B, 2005) |
| "We present a female with premature birth, polyhydramnios, congenital apnea, cranial nerve palsies, orofacial and limb anomalies." | 7.72 | A lethal association of congenital apnea with brainstem tegmental necrosis. ( Barboriak, D; Cummings, TJ; Delong, GR; Moya, MP, 2004) |
| "3%) had been enrolled in the randomized, placebo-controlled Caffeine for Apnea of Prematurity trial between 1999 and 2004." | 5.16 | Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. ( Anderson, PJ; Asztalos, EV; Barrington, KJ; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2012) |
| "Methylxanthine therapy reduces the frequency of apnea and the need for mechanical ventilation." | 4.82 | Methylxanthine therapy for apnea of prematurity: evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial. ( Schmidt, B, 2005) |
| "We present a female with premature birth, polyhydramnios, congenital apnea, cranial nerve palsies, orofacial and limb anomalies." | 3.72 | A lethal association of congenital apnea with brainstem tegmental necrosis. ( Barboriak, D; Cummings, TJ; Delong, GR; Moya, MP, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schmidt, B | 2 |
| Anderson, PJ | 1 |
| Doyle, LW | 1 |
| Dewey, D | 1 |
| Grunau, RE | 1 |
| Asztalos, EV | 1 |
| Davis, PG | 1 |
| Tin, W | 1 |
| Moddemann, D | 1 |
| Solimano, A | 1 |
| Ohlsson, A | 1 |
| Barrington, KJ | 1 |
| Roberts, RS | 1 |
| Moya, MP | 1 |
| Delong, GR | 1 |
| Barboriak, D | 1 |
| Cummings, TJ | 1 |
| Levitt, GA | 1 |
| Mushin, A | 1 |
| Bellman, S | 1 |
| Harvey, DR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Methylxanthines in Very Low Birthweight Infants[NCT00182312] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 1999-10-31 | Completed | ||
| Pharmacokinetics (PK) and Safety of Caffeine in Neonates With Hypoxic Ischemic Encephalopathy Receiving Therapeutic Hypothermia[NCT05295784] | Phase 1 | 18 participants (Anticipated) | Interventional | 2024-06-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for apnea and Deafness
| Article | Year |
|---|---|
Methylxanthine therapy for apnea of prematurity: evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial.
Topics: Aging; Apnea; Blindness; Cerebral Palsy; Cognition Disorders; Deafness; Follow-Up Studies; Humans; I | 2005 |
1 trial available for apnea and Deafness
| Article | Year |
|---|---|
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |
2 other studies available for apnea and Deafness
| Article | Year |
|---|---|
A lethal association of congenital apnea with brainstem tegmental necrosis.
Topics: Abnormalities, Multiple; Apnea; Brain Stem; Calcinosis; Cerebral Hemorrhage; Cerebral Ventricles; De | 2004 |
Outcome of preterm infants who suffered neonatal apnoeic attacks.
Topics: Apnea; Child, Preschool; Deafness; Developmental Disabilities; Humans; Infant; Infant, Newborn; Infa | 1988 |